In this episode, Professor Partha Kar looks into the ongoing inequalities in uptake and awareness of continuous glucose monitoring (CGM). Despite recent advances in access to CGM through the NHS for people with type 1 diabetes, there exist both racial and socioeconomic disparities in use of this technology.1
In addition, Professor Kar considers aspects of CGM access for people with type 1 and type 2 diabetes and examines the causes of, and potential solutions to, inequalities in the use of CGM.
Catherine JP, et al. EClinicalMedicine. 2021;42:101186.
UK Prescribing information for Toujeo® (insulin glargine 300 U/mL) can be accessed by clicking here.
Republic of Ireland Prescribing information for Toujeo® (insulin glargine 300 U/mL) can be accessed by clicking here.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to Sanofi Tel: 0800 090 2314. Alternatively, send via email to [email protected]
The content of this website is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition.
Any distribution or duplication of the information contained herein is strictly prohibited.